Global Batten Disease Treatment Market – Industry Trends and Forecast to 2030

Global Batten Disease Treatment Market, By Types (Congenital NCL, Infantile NCL, Late Infantile NCL and Adult NCL), Drugs (Cerliponase Alfa, Valproic Scid, and Levetiracetam), Therapy (Occupational Therapy and Physical Therapy), Treatment (Medication and Supportive Care), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), End Users (Hospitals, Homecare, Specialty Clinics, and Others) – Industry Trends and Forecast to 2030.

Batten Disease Treatment Market Analysis and Size

The rise in neurological disorders is a major driving factor for the market growth. Furthermore, the increase in the investment of biotechnology and pharmaceutical industries in research and development is further anticipated to propel the growth of the batten disease treatment market. Moreover, the growing demand for better treatment methods is further estimated to cushion the growth of the batten disease treatment market.

Data Bridge Market Research analyses that the Batten Disease Treatment Market, which was USD 41.39 million in 2022, would rocket up to USD 57.89 million by 2030 and is expected to undergo a CAGR of 5.4% during the forecast period. "Congenital NCL" dominates the type segment of the Batten disease treatment Market owing to the high prevalence of this type of disease. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Batten Disease Treatment Market Scope and Segmentation

Market Definition

Batten disease is a rare, inherent, and fatal nervous system disorder. It is the most general form of a group of disorders named the neuronal ceroid lipofuscinoses (NCLs), which is known to be a class of life-limiting neurogenerative genetic diseases that are triggered because of abnormality of genes resulting in their inability to synthesize the essential protein.

Batten Disease Treatment Market Dynamics

Drivers

• Rising incidences of neurological diseases

The growing prevalence of neurological diseases is among the essential factors intensifying the growth and demand for the batten disease treatment market. This, in turn, has carved the way for market development.

• Research and development proficiencies

Rising expenditure for research and development proficiencies, especially in developed and developing economies, about medical drugs and devices will further create lucrative market growth opportunities. Research and development proficiencies being conducted to develop medical drugs also bolstered the market growth rate.

• Growing investment in healthcare facilities

Surging focus on improving the condition of healthcare facilities and improving the overall healthcare infrastructure is another important factor fostering market growth. The rising number of partnerships and strategic collaborations between the public and private players about funding and application of new and improved technology further creates lucrative market opportunities.  

Opportunities

• Upsurge in the public-private funding

Furthermore, an upsurge in the public-private funding for target research activities, rising prevalence of neurogenerative diseases, and rising product innovations and development owing to technological advancements worldwide will extend profitable opportunities for the market players in the forecast period of 2023 to 2030. Likewise, the rise in worldwide healthcare expenses will further provide potential opportunities for the growth of the batten disease treatment market in the coming years.

Restraints/Challenges

• Rise in the price of treatment

On the other hand, rise in the price of treatment, high cost associated with research and development proficiencies, and limited infrastructural facilities, at present, only one drug is accepted for batten disease, which is further projected to impede the growth of the batten disease treatment market in the timeline period and dearth of awareness in the backward economies are expected to obstruct market growth. Also, the lack of favorable reimbursement scenarios and technology penetration in developing economies and the lack of suitable infrastructure in low- and middle-income countries are projected to challenge the market in the forecast period of 2023-2030.

The global batten disease treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Batten disease treatment Market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In August 2020, Abeona Therapeutics announced initiating a Phase 1/2 clinical trial of ABO-202, a gene therapy for CLN1 disease.

• In July 2020, Regenxbio announced initiating a Phase 1/2 clinical trial of RGX-181, a gene therapy for CLN2 disease.

Global Batten Disease Treatment Market Scope

The global batten disease treatment market is segmented on the basis of types, drugs, therapy, treatment, route of administration, end users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

 Types

• Congenital NCL
• Infantile NCL
• Late Infantile NCL
• Adult NCL

Drug

• Cerliponase Alfa
• Valproic Scid
• Levetiracetam

Therapy

• Occupational Therapy
• Physical Therapy

Treatment

• Medication
• Supportive Care

Route of Administration

• Oral
• Parenteral

End Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy

Batten Disease Treatment Market Regional Analysis/Insights

The Batten disease treatment Market is analyzed, and market size insights and trends are provided by country, type, drug, therapy, treatment, route of administration, end users, and distribution channel as referenced above.

The countries covered in this market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina and rest of South America.

North America dominates the Batten Disease Treatment Market because of the strong base of healthcare facilities, the presence of major players in the market, increases cases of neurological diseases among the population, and the rising number of research activities in this region.   

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in healthcare facilities, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The Batten Disease Treatment Market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Batten disease treatment Market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Batten disease treatment Market. The data is available for historic period 2010-2020.

Competitive Landscape and Batten Disease Treatment Market Share Analysis

The Batten disease treatment Market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Batten disease treatment Market.

Some of the major players operating in the Batten Disease Treatment Market are:

• Novartis AG (Switzerland)
• Abeona Therapeutics Inc. (U.S.)
• Alexion Pharmaceuticals Inc. (U.S.)
• Amicus Therapeutics (U.S.)
• Lysogene (France)
• Biogen (U.S.)
• BioMarin Pharmaceutical Inc. (U.S.)
• Denali Therapeutics (U.S.)
• Dimension Therapeutics, Inc. (U.S.)
• Edison Pharmaceuticals (U.S.)
• GeneTx Biotherapeutics LLC (U.S.)
• Orchard Therapeutics (U.K.)
• Passage Bio (U.S.)
• Teva Pharmaceuticals Industries Ltd. (Ireland)
• Zydus Cadila (India)
• Mylan (U.S.)
• Regenxbio Inc. (U.S.)